^
    17d
    Integrating STING Activation with Programmed Death-Ligand 1 Inhibition: Novel Approaches for Cancer Treatment. (PubMed, Crit Rev Oncol Hematol)
    In contrast, early-phase clinical trials of STING agonists, including ADU-S100, SYNB1891, IMSA101, and MK-1454, have shown acceptable safety and pathway engagement but generally modest and variable clinical responses, primarily reflected by low objective response rates and limited disease stabilization. We highlight emerging drug delivery platforms, such as nanocarriers, antibody-drug conjugates, and exosome-based systems, as key modulators of efficacy and safety, and emphasize the importance of biomarker-guided approaches for patient stratification and trial optimization. By integrating biological insight with translational feasibility, this review provides a framework for advancing STING-based combination immunotherapy toward more durable and personalized cancer treatment.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • STING (stimulator of interferon response cGAMP interactor 1)
    |
    PD-L1 expression
    |
    ADU-S100 • IMSA101 • SYNB1891 • ulevostinag (MK-1454)
    almost2years
    Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants (clinicaltrials.gov)
    P1, N=32, Terminated, Synlogic | N=70 --> 32 | Recruiting --> Terminated; Business reasons
    Enrollment change • Trial termination • Combination therapy • Metastases
    |
    Tecentriq (atezolizumab) • SYNB1891
    almost5years
    [VIRTUAL] Intratumoral injection of SYNB1891, a synthetic biotic designed to activate the innate immune system, demonstrates target engagement in humans including intratumoral STING activation (AACR 2021)
    Repeat IT injection of SYNB1891 as monotherapy is safe and well-tolerated up to at least 3x107 cells and shows evidence of STING pathway target engagement. These data support the continued dose escalation of SYNB1891 as monotherapy, and initiation of Arm 2 in combination with atezolizumab.
    PD(L)-1 Biomarker • IO biomarker
    |
    IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • PD-L2 (Programmed Cell Death 1 Ligand 2) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • CD4 (CD4 Molecule) • STING (stimulator of interferon response cGAMP interactor 1) • GZMA (Granzyme A) • IFIT1 (Interferon Induced Protein With Tetratricopeptide Repeats 1) • IL1R1 (Interleukin 1 receptor, type I) • TNFSF10 (TNF Superfamily Member 10)
    |
    Tecentriq (atezolizumab) • SYNB1891